Hesperidin

Pharmacology & Research

Hesperidin — hesperetin-7-O-rutinoside, the characteristic flavanone of citrus — has a clinical reputation that two facts complicate. First, the strongest evidence, for venous disease and haemorrhoids, is not really about hesperidin: it belongs to the combination drug MPFF (micronised purified flavonoid fraction, Daflon) ≈ 90% diosmin + 10% hesperidin, in which hesperidin is the minority partner ^{6Reference 6Lyseng-Williamson KA · 2003ReviewMicronised purified flavonoid fraction — a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoidsView study →}. Second, hesperidin is a prodrug: its rutinose sugar blocks small-intestinal absorption, so gut bacteria in the colon must cleave it to the aglycone hesperetin before anything is absorbed — making exposure low, delayed and microbiome-dependent ^{15,16Reference 15Manach C et al. · 2003Bioavailability in humans of the flavanones hesperidin and narirutin after ingestion of orange juiceView study →Reference 16Actis-Goretta L et al. · 2015Gastrointestinal absorption and metabolism of hesperetin-7-O-rutinoside and hesperetin-7-O-glucoside in healthy humansView study →}. The genuinely pure-hesperidin human data are the smaller endothelial-function studies. Read the venous evidence as evidence for the diosmin combination, and the vascular-biomarker evidence as the (thinner) case for the molecule itself.

1. Venous disease & haemorrhoids (diosmin+hesperidin)

The main clinical area — and a combination drug. For chronic venous insufficiency, the Cochrane phlebotonics review (53 RCTs, ~6,013 people) found moderate-certainty evidence that phlebotonics probably slightly reduce oedema, with little/no effect on quality of life or ulcer healing and a probable rise in adverse events ^{1Reference 1Martinez-Zapata MJ et al. · 2020Systematic reviewPhlebotonics for venous insufficiencyView study →}. For haemorrhoids, a Cochrane review (20 RCTs, 2,334 patients) found significant benefit for bleeding, pruritus, discharge and overall improvement (but not pain) ^{2Reference 2Perera N et al. · 2012Systematic reviewPhlebotonics for haemorrhoidsView study →}, echoed by a flavonoid meta-analysis ^{3Reference 3Alonso-Coello P et al. · 2006Meta-analysisMeta-analysis of flavonoids for the treatment of haemorrhoidsView study →} and MPFF-specific meta-analyses ^{4,5Reference 4Sheikh P et al. · 2020Meta-analysisMicronised purified flavonoid fraction in haemorrhoid disease — a systematic review and meta-analysisView study →Reference 5Fu H et al. · 2022Meta-analysisEfficacy and safety of micronised purified flavonoid fractions for postoperative haemorrhoid complications — a systematic review and meta-analysisView study →}.

Gap: the tested agent is MPFF (≈90% diosmin, 10% hesperidin) — a diosmin-dominant combination, short-term, with methodological and industry-sponsorship concerns ^{6Reference 6Lyseng-Williamson KA · 2003ReviewMicronised purified flavonoid fraction — a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoidsView study →}. This is genuinely the strongest clinical bucket, but attributing it to pure hesperidin is like crediting oxerutin trials to plain rutin. For pure hesperidin, venous evidence collapses to roughly 20–25% ^{1,2Reference 1Martinez-Zapata MJ et al. · 2020Systematic reviewPhlebotonics for venous insufficiencyView study →Reference 2Perera N et al. · 2012Systematic reviewPhlebotonics for haemorrhoidsView study →}.

2. Endothelial function & blood pressure

The best genuinely-pure-hesperidin signal. A crossover RCT showed that isolated hesperidin reproduced orange juice’s improvement in postprandial microvascular endothelial reactivity and diastolic BP — causally linking hesperidin to the juice effect ^{7Reference 7Morand C et al. · 2011RCTHesperidin contributes to the vascular protective effects of orange juice — a randomised crossover study in healthy volunteersView study →}. In metabolic-syndrome patients, pure hesperidin 500 mg/day for 3 weeks improved flow-mediated dilation and lowered CRP and adhesion markers ^{8Reference 8Rizza S et al. · 2011Clinical trialCitrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndromeView study →}, and a larger trial found hesperidin-enriched orange juice reduced systolic and pulse pressure in pre-/stage-1 hypertensives ^{9Reference 9Valls RM et al. · 2021RCTEffects of hesperidin in orange juice on blood and pulse pressures in mildly hypertensive individuals — a randomised controlled trial (Citrus study)View study →}, with nutrigenomic work showing hesperidin drives most of orange juice’s anti-inflammatory gene-expression changes ^{10Reference 10Milenkovic D et al. · 2011RCTHesperidin displays relevant role in the nutrigenomic effect of orange juice on blood leukocytes in human volunteers — a randomised controlled crossover studyView study →}.

Gap: all endpoints are surrogates (FMD, BP, biomarkers), samples small (except the enriched-juice trial), durations weeks, and several are delivered via the orange-juice matrix (which also carries vitamin C, folate and sugars). No cardiovascular hard-outcome trials exist ^{8,9Reference 8Rizza S et al. · 2011Clinical trialCitrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndromeView study →Reference 9Valls RM et al. · 2021RCTEffects of hesperidin in orange juice on blood and pulse pressures in mildly hypertensive individuals — a randomised controlled trial (Citrus study)View study →}.

3. Metabolic markers — glucose & lipids

Weak and inconsistent. A dedicated meta-analysis concluded hesperidin has no significant effect on fasting glucose, insulin or HOMA-IR ^{11Reference 11Shams-Rad S et al. · 2020Meta-analysisHesperidin supplementation has no effect on blood glucose control — a systematic review and meta-analysis of randomised controlled clinical trialsView study →}, and a lipids/BP meta-analysis was largely null across cholesterol fractions ^{12Reference 12Mohammadi M et al. · 2019Meta-analysisHesperidin, a major flavonoid in orange juice, might not affect lipid profile and blood pressure — a systematic review and meta-analysis of randomised controlled clinical trialsView study →}; newer meta-analyses hint at small LDL/BP benefits but with inconsistent direction and small effect sizes ^{13Reference 13Shylaja H et al. · 2024Meta-analysisEffect of hesperidin on blood pressure and lipid profile — a systematic review and meta-analysis of randomised controlled trialsView study →}.

Gap: small trials, heterogeneous doses and forms, mostly short-term; the strongest dedicated meta-analysis is null for glucose. (COVID-19 interest ^{14Reference 14Dhingra AK et al. · 2023ReviewHesperidin — a potential therapeutic agent against COVID-19 (in-silico/hypothesis review)View study →} is in-silico/hypothetical — no robust clinical efficacy.) Net: weak ^{11,12Reference 11Shams-Rad S et al. · 2020Meta-analysisHesperidin supplementation has no effect on blood glucose control — a systematic review and meta-analysis of randomised controlled clinical trialsView study →Reference 12Mohammadi M et al. · 2019Meta-analysisHesperidin, a major flavonoid in orange juice, might not affect lipid profile and blood pressure — a systematic review and meta-analysis of randomised controlled clinical trialsView study →}.

Mechanisms

Target / pathway	Effect	Active species	Relevant to
Venotonic / capillary-protective	↑ venous tone, ↓ capillary permeability, ↓ leukocyte–endothelium adhesion	mostly diosmin (in MPFF); hesperidin contributory	venous insufficiency, haemorrhoids
Endothelial NO / vasodilation	hesperetin stimulates endothelial nitric oxide → ↑ FMD, ↓ BP	hesperetin (aglycone)	endothelial function, blood pressure
Anti-inflammatory	↓ CRP, adhesion molecules; NF-κB / leukocyte gene modulation	hesperidin / hesperetin	inflammation, endothelial function
Prodrug → hesperetin (microbiome-gated)	colonic bacteria cleave the rutinoside; hesperetin absorbed	conversion step	explains variability across all applications

Pharmacokinetics

Hesperidin is a poorly-absorbed prodrug for hesperetin, for a specific structural reason: its rutinose (rhamnose-glucose) sugar resists small-intestinal enzymes. A jejunal-perfusion study made this unambiguous — perfused hesperetin-7-O-rutinoside was ~80% recovered unabsorbed with essentially no hesperetin in blood, whereas the corresponding 7-O-glucoside was rapidly absorbed at that site ^{16Reference 16Actis-Goretta L et al. · 2015Gastrointestinal absorption and metabolism of hesperetin-7-O-rutinoside and hesperetin-7-O-glucoside in healthy humansView study →}. So absorption is deferred to the colon, where microbiota (Bifidobacteria prominent) strip the rhamnose and liberate hesperetin, which is then conjugated to glucuronides/sulfates before reaching the circulation ^{17Reference 17Amaretti A et al. · 2015Hydrolysis of the rutinose-conjugated flavonoids rutin and hesperidin by the gut microbiota and bifidobacteriaView study →}. The result is a plasma appearance that is delayed, blunted and microbiome-dependent: after orange juice, flavanone metabolites did not appear until ~3 h, peaked at 5–7 h (a Tmax consistent with distal/colonic absorption), and urinary recovery was low and saturable ^{15Reference 15Manach C et al. · 2003Bioavailability in humans of the flavanones hesperidin and narirutin after ingestion of orange juiceView study →}. This is the same rutinose handicap that limits rutin (→ quercetin).

The corollary is that formulation governs exposure. Removing the rhamnose to leave hesperetin-7-O-glucoside (“G-hesperidin”) relocates absorption to the small intestine and raises bioavailability with a shorter Tmax in a human crossover trial ^{18,19Reference 18Nielsen IL et al. · 2006RCTBioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans — a randomised, double-blind, crossover trialView study →Reference 19Yamada M et al. · 2006AnimalBioavailability of glucosyl hesperidin in ratsView study →}; micronisation (sub-2-µm particles, as in the diosmin-hesperidin drug) improves dissolution of an otherwise near-insoluble solid ^{6Reference 6Lyseng-Williamson KA · 2003ReviewMicronised purified flavonoid fraction — a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoidsView study →}. The practical upshot: plasma hesperetin from ordinary hesperidin is low and highly person-to-person variable (it tracks the microbiota), and a milligram figure says little about delivered exposure without the form.

Clinical trials

Hesperidin’s biggest clinical footprint is the diosmin+hesperidin combination (MPFF/Daflon) in venous disease and haemorrhoids — a diosmin-dominant drug. Pure-hesperidin trials are smaller and cluster in cardiovascular/endothelial surrogate endpoints; metabolic trials are mostly null.

Diosmin+hesperidin (MPFF)	Pure hesperidin (CV)	Metabolic	COVID
Many RCTs + Cochrane	Several small RCTs	Several (mostly null)	In-silico / hypothesis

Last checked: July 2026.

Isolate vs. Plant Studies

Hesperidin’s evidence is easy to over-credit in two directions. The venous/haemorrhoid clinical record is a combination drug — MPFF is ≈90% diosmin, so its efficacy is diosmin-led, and “hesperidin for varicose veins” borrows credit from a molecule it is only a minor partner to ^{1,6Reference 1Martinez-Zapata MJ et al. · 2020Systematic reviewPhlebotonics for venous insufficiencyView study →Reference 6Lyseng-Williamson KA · 2003ReviewMicronised purified flavonoid fraction — a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoidsView study →}. (Diosmin is itself partly manufactured from hesperidin, so they are chemically linked — but the clinical agent is diosmin-dominant.) The systemic pharmacology is really hesperetin’s: because hesperidin is cleaved to hesperetin before absorption, the endothelial-NO mechanism and circulating activity belong to the aglycone, not the intact glycoside ^{16,17Reference 16Actis-Goretta L et al. · 2015Gastrointestinal absorption and metabolism of hesperetin-7-O-rutinoside and hesperetin-7-O-glucoside in healthy humansView study →Reference 17Amaretti A et al. · 2015Hydrolysis of the rutinose-conjugated flavonoids rutin and hesperidin by the gut microbiota and bifidobacteriaView study →}. Within this database hesperidin appears only as an occurrence-level constituent — the most representative flavonoid of couchgrass rhizome tea, present in mullein leaf, and part of the (low, unquantified) flavonoid fraction of buchu — with no herb-level clinical claim; the venous evidence in the broader literature is pharmaceutical (MPFF), not from these herbs. Keep hesperidin (the glycoside) distinct from hesperetin (the aglycone, its own page) and from diosmin (the co-drug).

Prevalence in Nature

Hesperidin is the characteristic flavanone glycoside of citrus (Rutaceae) — sweet orange, mandarin/tangerine, lemon, lime and sweet lime — and it is overwhelmingly a peel compound: the albedo (white pith), flavedo and segment membranes hold roughly an order of magnitude more than the juice or flesh ^{22Reference 22Garg A et al. · 2001Chemistry and pharmacology of the citrus bioflavonoid hesperidinView study →}. The richest-to-leanest pattern runs dried/immature (green) citrus peel ≫ albedo ≫ mature peel > juice/flesh ≫ peppermint leaf. Immature “green” citrus is the extreme — the peel of Citrus unshiu reaches up to ~6.25% dry weight hesperidin, which is why immature-citrus drugs (zhi shi, chenpi) are the commercial extraction feedstock ^{25Reference 25Lu Y et al. · 2006Citrus flavonoids in fruit and traditional Chinese medicinal food ingredients in ChinaView study →}. Juice is far lower and variable with ripeness and processing — orange juice ~20–60, tangerine ~8–46, lemon ~4–41 mg/100 mL ^{22,24Reference 22Garg A et al. · 2001Chemistry and pharmacology of the citrus bioflavonoid hesperidinView study →Reference 24Silva LC et al. · 2014Determination of flavanones in orange juices obtained from different sources by HPLC/DADView study →} — so the Content-by-Source chart shows the peel/albedo tissues where hesperidin actually concentrates, with juice values given here in prose. Outside citrus, the only dietary source of note is the mint family: peppermint carries genuine but ~500× lower hesperidin than citrus peel ^{26Reference 26Ćavar Zeljković S et al. · 2021Phenolic compounds and biological activity of selected Mentha speciesView study →}. (Grapefruit is not a hesperidin source — its dominant flavanone is naringin.)

Biosynthetically, the flavonoid pathway builds naringenin, which is 3′-hydroxylated and 4′-O-methylated to hesperetin, and a 7-O-glucosyltransferase plus a rhamnosyltransferase then attach rutinose (rhamnosyl-1,6-glucose) at the 7-hydroxyl to give hesperidin — accumulating as a UV-protective storage flavonoid in peel and immature-fruit vacuoles, where it often crystallises. There is essentially no non-plant source; dietary intake is effectively all citrus, with a trace from mint.

Discovery & Synthesis

The name is mythological: “hesperidin” derives, via the botanical term hesperidium (the name for the specialised berry of citrus fruits), from the Hesperides of Greek myth — the nymphs who tended a garden of golden apples, an image antiquity linked to the golden fruit of citrus. The compound is conventionally credited to the French pharmacist Lebreton, who isolated it around 1828 from the albedo of orange peel, making it one of the earliest flavonoids characterised — though this attribution predates the modern literature index and cannot be confirmed against a primary source, so treat it as the standard historical account.

Structurally hesperidin is the 7-O-rutinoside of hesperetin. Hesperetin — the aglycone and the actually-absorbed species — is 3′,5,7-trihydroxy-4′-methoxyflavanone: a flavanone with a distinctive 4′-methoxy group; in hesperidin the 7-hydroxyl carries the rutinose disaccharide whose rhamnose cap causes the poor absorption above. Commercially hesperidin is extracted from citrus peel, a high-volume byproduct of the juice industry where it is abundant (and can precipitate as crystals in juice and peel); to overcome bioavailability, industry makes enzymatically modified glucosyl-hesperidin (G-hesperidin), appending glucose to improve solubility and shift absorption proximally ^{18,19Reference 18Nielsen IL et al. · 2006RCTBioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans — a randomised, double-blind, crossover trialView study →Reference 19Yamada M et al. · 2006AnimalBioavailability of glucosyl hesperidin in ratsView study →}. Total synthesis has confirmed the structure but is not the commercial route.

Patents: not yet researched (future patent-loop pass).

Toxicity & Safety

Hesperidin is a citrus flavanone with a long dietary history and low toxicity — the poor absorption that frustrates its pharmacology also limits systemic exposure. In controlled trials (typically ~500–1,000 mg/day for weeks to months) it is generally well tolerated, with meta-analyses reporting no serious adverse events and only sporadic, mild, mostly gastrointestinal complaints ^{20,21Reference 20Sridhar V et al. · 2014In vitroEvaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using felodipine and hesperetin in Wistar rats and everted rat gut sacs in vitroView study →Reference 21Khorasanian AS et al. · 2023Meta-analysisThe effects of hesperidin supplementation on cardiovascular risk factors in adults — a systematic review and dose-response meta-analysisView study →}; no human toxic dose is established.

On interactions, the citrus-flavonoid CYP story must be stated carefully to avoid the grapefruit confusion: the clinically important grapefruit-drug interaction is driven by furanocoumarins, not flavonoids, and hesperidin is a sweet-orange flavonoid — it does not carry grapefruit’s warning by association. That said, the aglycone hesperetin inhibits CYP3A4 and P-glycoprotein in preclinical models and raised exposure to the CYP3A/P-gp substrate felodipine in rats ^{20Reference 20Sridhar V et al. · 2014In vitroEvaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using felodipine and hesperetin in Wistar rats and everted rat gut sacs in vitroView study →}; two hedges apply — these effects are largely in-vitro/animal at concentrations free hesperetin rarely reaches from oral hesperidin, and the intact glycoside is a weaker inhibitor than the aglycone. So the reasonable framing is biologically plausible, clinically unproven: flag caution for concentrated extracts co-administered with narrow-therapeutic-index CYP3A4/P-gp substrates, and a conservative caution alongside anticoagulant/antiplatelet therapy, without overstating either.

Dosage

Human cardiovascular/endothelial trials of pure hesperidin have used around 500 mg/day ^{8Reference 8Rizza S et al. · 2011Clinical trialCitrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndromeView study →}, while the venous-disease evidence uses the diosmin+hesperidin combination (MPFF) at ~450–1,000 mg/day — a different, diosmin-dominant agent ^{6Reference 6Lyseng-Williamson KA · 2003ReviewMicronised purified flavonoid fraction — a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoidsView study →}. Because hesperidin is a poorly-absorbed, microbiome-gated prodrug, the delivered hesperetin exposure depends heavily on the form (micronised or glucosyl-hesperidin absorb better) ^{18Reference 18Nielsen IL et al. · 2006RCTBioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans — a randomised, double-blind, crossover trialView study →}.

These are doses used in research and are not a personal recommendation — the strong venous evidence is for the diosmin combination, not pure hesperidin, and individual response is limited by absorption and the gut microbiome.

References